Comparing Amgen (NASDAQ:AMGN) and Cellectis (NASDAQ:CLLS)

Amgen (NASDAQ:AMGN) and Cellectis (NASDAQ:CLLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Amgen and Cellectis, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen 0 8 10 0 2.56
Cellectis 0 2 3 0 2.60

Amgen presently has a consensus price target of $207.00, suggesting a potential upside of 17.56%. Cellectis has a consensus price target of $35.25, suggesting a potential upside of 136.74%. Given Cellectis’ stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than Amgen.

Earnings and Valuation

This table compares Amgen and Cellectis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amgen $23.75 billion 4.52 $8.39 billion $14.40 12.23
Cellectis $21.43 million 28.91 -$78.69 million ($1.93) -7.72

Amgen has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.


This table compares Amgen and Cellectis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amgen 34.00% 71.02% 14.07%
Cellectis -401.24% -14.85% -13.24%

Risk and Volatility

Amgen has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

77.3% of Amgen shares are held by institutional investors. Comparatively, 30.6% of Cellectis shares are held by institutional investors. 0.3% of Amgen shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Amgen pays an annual dividend of $5.80 per share and has a dividend yield of 3.3%. Cellectis does not pay a dividend. Amgen pays out 40.3% of its earnings in the form of a dividend. Amgen has increased its dividend for 8 consecutive years.


Amgen beats Cellectis on 11 of the 17 factors compared between the two stocks.

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.